Higgins John L's Form 4/A amendment
AmendedLigand Pharmaceuticals Inc (LGND) · filed Sep 22, 2022
- Accession no.
- 0000886163-22-000125
- Filed
- Sep 22, 2022
- Trade date
- Sep 16, 2022
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Sep 16, 2022
This filing lists 1 non-derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $268.1K. It was filed 6 days after the trade.
This amendment restates part of 0000886163-22-000122 (filed Sep 16, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Higgins John LCIK 0001208906 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2022 | Common Stock | SSaleDisposed | −1,000 | $88.06F2 | −$88,060 | 366,180 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000886163-22-000122 (filed Sep 16, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2022 | Common Stock | SSaleDisposed | −2,000 | $90.00 | −$180,000 | 367,180 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 16, 2022, due to an issue with the equity administration system of the company, the reporting person filed a Form 4 which inadvertently reported the sale of a higher number of shares than were actually sold by the reporting person. The correct number of shares sold is listed above.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $88.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.